Catalysts / STOK
Upcoming FDA decisions and readouts we track for Stoke Therapeutics, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for Stoke Therapeutics (STOK, listed on Nasdaq). They cover 2 programmes: Zorevunersen (Dravet syndrome) and STK-002 (Autosomal dominant optic atrophy).
First on the list: the Regulatory submission for Zorevunersen (Dravet syndrome), guided by the company to Q1 2027. The furthest-out event tracked is Q3 2027. By stage, the upcoming rows are 1 Phase 1 readout, 1 Phase 3 readout and 1 Regulatory submission.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: NDA vs BLA: the two kinds of US drug application; Clinical trial phases explained: Phase 1 to Phase 4; How to read a Phase 3 topline readout.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics STOK · Nasdaq | Zorevunersen | Dravet syndrome | Q1 2027 company guidance |
Regulatory submission | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Stoke Therapeutics STOK · Nasdaq | STK-002 | Autosomal dominant optic atrophy | H1 2027 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Stoke Therapeutics STOK · Nasdaq | Zorevunersen | Dravet syndrome | Q3 2027 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList